AstraZeneca Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
317 result(s) found, displaying 31 to 40
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Prescription medicine decision summaryTruqap (capivasertib), in combination with fulvestrant, is approved for the treatment of adult patients with locally advanced or metastatic breast cancer.
-
-
Prescription medicine decision summaryLokelma (sodium zirconium cyclosilicate hydrate) was approved for the treatment of hyperkalaemia in adult patients. Lokelma binds to potassium in the gut and is used to treat high levels of potassium in the blood.
-
Prescription medicine registrationActive ingredients: dapagliflozin propanediol monohydrate, sitagliptin phosphate monohydrate.
-
Designation or determinationProvisional determination
-
-
May-2024Prescription medicine evaluationActive ingredient: datopotamab deruxtecan.
-
May-2024Prescription medicine evaluationActive ingredient: datopotamab deruxtecan.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd